Biosimilar Antibodies
| Cat.No. | Product Name | Information | Isotype |
|---|---|---|---|
| A2947 | Briakinumab (Anti-IL-12) (IL-12a & IL-12b) | Briakinumab (anti-IL-12) (IL-12a & IL-12b) is a human monoclonal antibody directed against the human Interleukins 12 (IL-12) and 23 (IL-23), with immunomodulating activity. It has the potential to be used in the treatment of Crohn's disease. MW: 143.86 KD. | Human IgG1 |
| A2692 | Gosuranemab (Anti-Tau) | Gosuranemab (Anti-Tau) is a humanised monoclonal antibody against the extracellular N-terminal of tau in the interstitial fluid (ISF) and CSF released by neurons. It has the potential for research of Alzheimer’s disease (AD). MW: 150 kD. | Human IgG4SP |
| A2948 | Nipocalimab (Anti-FcRn) (FCGRT & B2M) | Nipocalimab (Anti-FcRn) (FCGRT & B2M) is a fully human monoclonal antibody that targets the neonatal crystallisable fragment receptor (FcRn) with potential immunomodulating activity. MW: 142.12 KD. | Human IgG1 |
| A2693 | Semorinemab (Anti-Tau) | Semorinemab (Anti-Tau) is a humanised IgG4 monoclonal antibody that targets the N-terminal domain of tau (amino acid residues 6-23). Semorinemab has the potential to be used in research on Alzheimer's disease. MW : 150 kD. | Human IgG4SP |
| A2949 | Cendakimab (Anti-IL-13) | Cendakimab (anti-IL-13) is a humanised, recombinant monoclonal antibody against the interleukin-13 (IL-13) molecule with the potential to treat allergic/inflammatory diseases (e.g., asthma and eosinophilic oesophagitis). MW: 146.44 KD. | Human IgG1 |
| A2694 | Anti-TGFb1 (SRK181) | Anti-TGFb1 (SRK181) is a monoclonal antibody directed against latent human transforming growth factor (TGF)-beta 1 with potential antineoplastic activity. MW : 150 kD. | Human IgG4SP |
| A2950 | Dectrekumab (Anti-IL-13) | Dectrekumab (anti-IL-13) is a humanised monoclonal antibody that targets interleukin-13 (IL-13). It has the potential to be used in inflammation and immunology-related research. MW: 146.16 KD. | Human IgG1 |
| A2951 | Anti-IL-13 (GSK 679586) | Anti-IL-13 (GSK 679586) is a humanised monoclonal IgG1 antibody against interleukin-13 (IL-13). It has the potential to treat chronic spontaneous urticaria. MW: 148.38 KD. | Human IgG1 |
| A2696 | Anti-TLR3 / CD283 (CNTO5429) | Anti-TLR3 / CD283 (CNTO5429) is a novel antibody that binds to the extracellular domain of TLR3 and inhibits poly(I:C)-induced inflammation. MW: 145.3 KD. | Human IgG2SA |
| A2952 | Anti-IL-13 (H2L6) | Anti-IL-13 (H2L6) is a humanized antibody against interleukin-13 (IL-13). MW: 146.16 KD. | Human IgG1 |
| A2697 | Enavatuzumab (Anti-TNFRSF12A / TWEAKR / CD266) | Enavatuzumab (Anti-TNFRSF12A / TWEAKR / CD266) is a humanised monoclonal antibody directed against the tumour necrosis factor-like weak inducer of apoptosis receptor (TWEAKR) with potential antineoplastic, immunomodulating and antiangiogenic activities. MW : 150 kD. | Human IgG1 |
| A2953 | Anti-IL-13 (IMA-026) | Anti-IL-13 (IMA-026) is a humanised IgG1 antibody targeted against interleukin 13 (IL-13) with the potential to treat chronic spontaneous urticaria. MW: 146.88 KD. | Human IgG1 |
| A2698 | Anti-TYRO3 (ELB031) | Anti-TYRO3 (ELB031) is a monoclonal antibody that targets TYRO3 and MERTK. | Human IgG1 |
| A2954 | Lebrikizumab (Anti-IL-13) | Lebrikizumab (anti-IL-13) is a humanised IgG4 monoclonal antibody against Interleukins 13 (IL-13) with immunosuppressive and anti-asthmatic activities. MW: 145.8 KD. | Human IgG4SP |
| A2699 | Timolumab (Anti-AOC3 / VAP1) | Timolumab (Anti-AOC3 / VAP1) is a fully human monoclonal antibody directed against vascular adhesion protein-1 (VAP-1). Timolumab has the potential to be used in research on chronic inflammatory diseases. MW : 150 kD. | Human IgG4SP |
| A2955 | Anti-IL-13 (M1295) | Anti-IL-13 (M1295) is a humanised antibody against interleukin-13 (IL-13). MW: 145.8 KD. | Human IgG1 |
| A2956 | Nofazinlimab (Anti-PDCD1 / PD-1 / CD279) | Nofazinlimab (anti-PDCD1/ PD-1 / CD279) is a humanised IgG4 monoclonal antibody targeting PD-1. Nofazinlimab has the potential to be used in unresectable hepatocellular carcinoma (uHCC) research. MW: 145.08 KD. | Human IgG4SP |
| A2701 | Anti-Complement C2 (ARGX-117) | Anti-Complement C2 (ARGX-117) is a monoclonal antibody that inhibits complement factor C2. It inhibits complement in a disease model for multifocal motor neuropathy. MW: 146.12 kD. | Human IgG1 |
| A2702 | Anti-GPR20 (DS-6157) | Anti-GPR20 (DS-6157) is a monoclonal antibody directed against the G protein-coupled receptor 20 (GPR20) with potential antineoplastic activity. MW : 150 kD. | Human IgG1 |
| A2958 | Anti-IL-15 (DISC0280) | Anti-IL-15 (DISC0280) is a human monoclonal antibody targeted against Interleukin-15 (IL-15). MW: 145.62 KD. | Human IgG1 |
Products are for research use only. Not for human use. We do not sell to patients.
©Copyright 2013 Selleck Chemicals. All Rights Reserved.